Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 19596954)

1.

Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer.

Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J.

Anticancer Res. 2009 Jul;29(7):2739-45.

2.

Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.

GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Tsuburaya A, Van Cutsem E, Buyse M.

Eur J Cancer. 2013 May;49(7):1565-77. doi: 10.1016/j.ejca.2012.12.016. Epub 2013 Jan 24. Review.

PMID:
23352439
3.

The use of lentinan for treating gastric cancer.

Ina K, Kataoka T, Ando T.

Anticancer Agents Med Chem. 2013 Jun;13(5):681-8. Review.

4.

Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy.

Ina K, Furuta R, Kataoka T, Kayukawa S, Yoshida T, Miwa T, Yamamura Y, Takeuchi Y.

World J Clin Oncol. 2011 Oct 10;2(10):339-43. doi: 10.5306/wjco.v2.i10.339.

5.

Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer.

Yoshino S, Watanabe S, Imano M, Suga T, Nakazawa S, Hazama S, Oka M.

Hepatogastroenterology. 2010 Jan-Feb;57(97):172-7.

PMID:
20422897
6.

[Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].

Akasaka O, Iwase S, Miwa H, Ando T, Morita S, Koh R, Kasama M, Matsueda R, Anan H.

Gan To Kagaku Ryoho. 2009 Nov;36(11):1833-7. Japanese.

PMID:
19920384
7.

High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.

Vidal O, Metges JP, Elizalde I, Valentíni M, Volant A, Molina R, Castells A, Pera M.

Br J Surg. 2009 Dec;96(12):1443-51. doi: 10.1002/bjs.6780.

PMID:
19918848
8.

Adjuvant chemotherapy for completely resected non-small-cell lung cancer.

Suehisa H, Toyooka S.

Acta Med Okayama. 2009 Oct;63(5):223-30. Review.

9.

Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening.

Autier P, Héry C, Haukka J, Boniol M, Byrnes G.

J Clin Oncol. 2009 Dec 10;27(35):5919-23. doi: 10.1200/JCO.2009.22.7041. Epub 2009 Nov 2. Review.

PMID:
19884547
10.

RANTES promoter genotype and gastric cancer risk in a Japanese population.

Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Hirata I, Arisawa T.

Anticancer Res. 2009 Oct;29(10):4265-9.

11.

[A case of recurrent gastric cancer during adjuvant chemotherapy with S-1, treated by S-1 combination chemotherapy].

Shibata N, Eto TA, Asada T, Takaya T, Tanaka S, Shimayama T, Imada S, Futami S, Hidaka H, Chijiiwa K.

Gan To Kagaku Ryoho. 2009 Oct;36(10):1745-8. Japanese.

PMID:
19838040
12.

Retrospective analysis of concomitant Cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: a gynecologic oncology group study.

Kunos C, Tian C, Waggoner S, Rose PG, Lanciano R.

Int J Gynecol Cancer. 2009 Oct;19(7):1258-63. doi: 10.1111/IGC.0b013e3181b33ace.

PMID:
19823064
13.

Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.

Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, Tanabe S, Higuchi K, Sasaki T, Sekikawa T; Tokyo Cooperative Oncology Group (TCOG GI Group).

Jpn J Clin Oncol. 2009 Nov;39(11):713-9. doi: 10.1093/jjco/hyp099. Epub 2009 Oct 6.

14.

Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).

Koeth O, Zahn R, Gitt AK, Bauer T, Juenger C, Senges J, Zeymer U; Maximal Individual Therapy in Acute Myocardial Infarction Plus Study Group.

Am J Cardiol. 2009 Oct 15;104(8):1074-7. doi: 10.1016/j.amjcard.2009.05.054.

PMID:
19801027
15.

Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer.

Jensen EH, Abraham A, Jarosek S, Habermann EB, Al-Refaie WB, Vickers SA, Virnig BA, Tuttle TM.

Surgery. 2009 Oct;146(4):706-11; discussion 711-3. doi: 10.1016/j.surg.2009.06.056.

PMID:
19789030
16.

Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.

Ozols RF.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S60-73. Review.

PMID:
19780247
17.

Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer.

d'Amato TA, Ashrafi AS, Schuchert MJ, Alshehab DS, Seely AJ, Shamji FM, Maziak DE, Sundaresan SR, Ferson PF, Luketich JD, Landreneau RJ.

Ann Thorac Surg. 2009 Oct;88(4):1079-85. doi: 10.1016/j.athoracsur.2009.06.025.

PMID:
19766784
18.

Update on erythropoiesis-stimulating agents and clinical trials in oncology.

Aapro M, Spivak JL.

Oncologist. 2009;14 Suppl 1:6-15. doi: 10.1634/theoncologist.2009-S1-6. Review.

19.

Gastric cancer: predictors of recurrence when lymph-node dissection is inadequate.

Uña E.

World J Surg Oncol. 2009 Sep 17;7:69. doi: 10.1186/1477-7819-7-69.

20.

Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy.

Bruins HM, Huang GJ, Cai J, Skinner DG, Stein JP, Penson DF.

J Urol. 2009 Nov;182(5):2182-7. doi: 10.1016/j.juro.2009.07.017. Epub 2009 Sep 15.

PMID:
19758623
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk